Recent KYMR News
- Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting • GlobeNewswire Inc. • 05/14/2024 02:00:00 PM
- Kymera Therapeutics to Participate in Upcoming May Investor Conferences • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 • GlobeNewswire Inc. • 04/25/2024 11:00:00 AM
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting • GlobeNewswire Inc. • 04/08/2024 11:00:00 AM
- Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting • GlobeNewswire Inc. • 03/08/2024 03:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:21:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:12:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:12:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:50:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:47:58 PM
- Kymera Therapeutics to Participate in Upcoming March Investor Conferences • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2024 09:22:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/22/2024 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:10:10 PM
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 • GlobeNewswire Inc. • 02/15/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/10/2024 12:47:01 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:22:29 PM
- Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
- Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs • GlobeNewswire Inc. • 01/09/2024 02:17:00 PM
- Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 01/09/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:11:55 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/05/2024 09:02:25 PM
- Kymera Therapeutics Announces Pricing of $275 Million Public Offering • GlobeNewswire Inc. • 01/05/2024 11:00:00 AM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM